LABORATORY AND CLINICAL INVESTIGATIONS ON FOSFOMYCIN FOR INTRAVENOUS INJECTION
スポンサーリンク
概要
- 論文の詳細を見る
1. In determining MIC of fosfomycin-Na (abbr. FOM-Na), an antibacterial activity against <I>Proteus</I> group was exhibited stronger by means of our synthetic medium or nutrient medium. To the contrary, the antibacterial activity was more inhibited than the above cases, when NaCl or yeast extract, or these 2 were added to nutrient medium.<BR>2. FOM-Na concentrations in blood could be measured to 0.470μg/ml at the lowest by means of a cold superposing method.<BR>3. FOM-Na concentrations in blood began to decrease immediately after FOM-Na 1g (potency) was injected intravenously, and each mean values were 192μg/ml in 30 minutes, 144μg/ml in 1 hour, 32μg/ml in 3 hours, and2.7μg/ml in 6 hours.<BR>4. Mean urinary recovery ratios of FOM-Na were 25% within 1 hour after the intravenous injection, 40% within 3 hours, 21% within 6 hours. About 86% was excreted thus within 6 hours, and more than 20 times antibacterial activity was observed in comparison with that of blood concentration.<BR>5. As it is well known, MIC of antibiotic varies with measurement conditions and compositions of measuring medium, and FOM-Na varied broadly too with these conditions.<BR>6. FOM-Na is an antibiotic which may be characterized by a good excretion from living body in comparison with other drugs.<BR>7. FOM-Na was administered clinically in the patients of cystitis due to secondary infection, and the effect was obtained in 9 cases out of 10 cases, though a relapse occurred in 2 effective cases after interruption of administration.<BR>Hepatic function, renal function, and general tests after intravenous injection of FOM-Na revealed no side effect which would be attributed to the drug.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.